In less than five hours from
now, President and CEO of Actinium Pharmaceuticals Dr. Kaushik J. Dave will be
presenting a corporate update at the Biotech Showcase™ 2014 in San Francisco,
CA.
The presentation starts at
4:30pm Pacific at the Wyndham Hotel. For those unable to join in person, the
company has provided the following webcast link:
http://www.media-server.com/m/p/qbc4c7nh.
Actinium Pharmaceuticals is
a biopharmaceutical company with a proprietary platform that combines the
precision targeting of monoclonal antibodies with the killing power of alpha
and beta radioisotopes, the former being the most potent cancer killing agents
in existence. Leveraging this platform and its ties with leading cancer
institutions, the company is focused on developing drugs for underserved
cancers with no approved drugs which have multi-billion dollar market
potential.
For more information on
Actinium Pharmaceuticals, visit www.actiniumpharmaceuticals.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
